Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS ONE. 2009; 4(6): e5776.
Published online 2009 Jun 2. doi:  10.1371/journal.pone.0005776
PMCID: PMC2685013

Phenotypic Characterization of Autoreactive B Cells—Checkpoints of B Cell Tolerance in Patients with Systemic Lupus Erythematosus

Wasif N. Khan, Editor


DNA-reactive B cells play a central role in systemic lupus erythematosus (SLE); DNA antibodies precede clinical disease and in established disease correlate with renal inflammation and contribute to dendritic cell activation and high levels of type 1 interferon. A number of central and peripheral B cell tolerance mechanisms designed to control the survival, differentiation and activation of autoreactive B cells are thought to be disturbed in patients with SLE. The characterization of DNA-reactive B cells has, however, been limited by their low frequency in peripheral blood. Using a tetrameric configuration of a peptide mimetope of DNA bound by pathogenic anti-DNA antibodies, we can identify B cells producing potentially pathogenic DNA-reactive antibodies. We, therefore, characterized the maturation and differentiation states of peptide, (ds) double stranded DNA cross-reactive B cells in the peripheral blood of lupus patients and correlated these with clinical disease activity. Flow cytometric analysis demonstrated a significantly higher frequency of tetramer-binding B cells in SLE patients compared to healthy controls. We demonstrated the existence of a novel tolerance checkpoint at the transition of antigen-naïve to antigen-experienced. We further demonstrate that patients with moderately active disease have more autoreactive B cells in both the antigen-naïve and antigen-experienced compartments consistent with greater impairment in B cell tolerance in both early and late checkpoints in these patients than in patients with quiescent disease. This methodology enables us to gain insight into the development and fate of DNA-reactive B cells in individual patients with SLE and paves the way ultimately to permit better and more customized therapies.


A wide variety of autoantibodies can be detected in patients with systemic lupus erythematosus (SLE), a high percentage of which bind to nuclear antigens [1] . Autoantibodies to dsDNA are essentially diagnostic of the disease. They are considered to be pathogenic as changes in their titer correlate with disease activity, and in murine models they clearly contribute to lupus nephritis [2]. Furthermore, they help induce an “interferon signature” that results from activation of toll-like receptor (TLR) 9 in dendritic cells by DNA-containing immune complexes [3] Moreover, elevated titers of anti-DNA antibodies can be seen in patients before the onset of clinical disease [4]. The mechanisms underlying the failure to maintain tolerance that allow for maturation and activation of autoreactive cells in SLE that are specific for DNA remain incompletely understood. Murine models have demonstrated the existence of multiple tolerance checkpoints during B cell maturation and activation, both before and after the germinal center response [5], [6], [7], [8], [9]. Defects in many of these checkpoints have been reported in murine models of lupus; thus, each appears necessary to stave off pathogenic autoreactivity [10], [11], [12], [13].

A significant percentage of the immature B cell repertoire is autoreactive [14]. Negative selection of autoreactive B cells is mediated by at least 3 processes: receptor editing, anergy induction and deletion [15], [16], [17]. Autoreactive B cells that escape early tolerance induction may mature to become marginal zone or follicular cells depending on the nature of the interaction of the B cell receptor (BCR) with antigen and the local microenvironment. Thus, autoreactive B cells can exist as short-lived plasma cells or germinal center-matured memory cells and long-lived plasma cells [18], [19]. In murine lupus models, autoreactive B cells are phenotypically heterogeneous; genetic background, hormonal milieu and antigen exposure all contribute to this diversity [11], [18], [19], [20], [21], [22]. These observations predict the presence of extensive heterogeneity in patients with lupus.

Repertoire analysis of immature, transitional and naïve B cells of patients with SLE and non-autoimmune individuals has confirmed the presence of multiple tolerance checkpoints [14], [23], [24], [25]. An assessment of the percentage of self- or poly-reactive B cells in early B cell populations has revealed two tolerance checkpoints, one at the immature to transitional junction and another one at the transitional to naïve junction. In a study of a small number of lupus patients, it is clear that both of these tolerance checkpoints are incompletely maintained in SLE [25]. Peripheral tolerance in patients with lupus also appears to be compromised. Autoreactive B cells expressing a VH4-34 encoded Ig heavy chain and possessing the 9G4 idiotype are present in the mature B cell repertoire but are excluded from the germinal center in non-autoimmune individuals; they can, however, be readily found within tonsillar germinal centers in SLE patients [26].

Our laboratory previously identified a peptide sequence (DWEYS) that behaves as a dsDNA mimetope [27]. Antibodies binding this sequence can cause renal disease and brain disease in mice, and are detected frequently in serum of patients with SLE and in cerebrospinal fluid of patients with neuropsychiatric manifestations of SLE [28], [29], [30], [31]. Immunization of BALB/c mice with an octameric form of this peptide (DWEYS-MAP) results in production of pathogenic IgG anti-dsDNA antibodies, glomerular immunoglobulin deposition, proteinuria as well as excitotoxic neuronal loss following a breach in the blood-brain barrier [28], [29], [32].

A fluorochrome–labeled tetrameric DWEYS peptide (DWEYS-tetramer), with a higher avidity for peptide reactive B cells than monomeric peptide [33] was generated to identify the peptide/dsDNA-cross-reactive B cell population in the murine immune response. Using this reagent, we have previously identified peptide dsDNA-cross-reactive B cells in mice immunized with DWEYS-MAP [34], [35]. Furthermore, we have shown that B cells in the peripheral blood of lupus patients that bind the DWEYS-tetramer are highly enriched for peptide and DNA reactivity [33].

This reagent therefore enables us to track the development and fate of a subset of dsDNA-reactive B cells in individual patients with SLE and gain insight into the heterogeneity of the anti-DNA response. It additionally may facilitate the identification of clinical subsets that may differ with respect to disease phenotype and disease activity and in response to therapy. Our goal in this cross-sectional study was to use the tetrameric DWEYS peptide to evaluate the frequency of these autoreactive B cells in antigen-naïve and antigen-experienced B cell subsets in SLE patients.


Phenotypic characterization of tetramer-binding B cells by flow cytometry

Subject Population

Peripheral blood was drawn in tubes containing citrate from 22 SLE patients fulfilling the revised ACR criteria for SLE who attended the outpatient Rheumatology clinics at Jacobi, Montefiore and Columbia University Medical Centers. The protocol was approved by the Institutional Review Boards at all three institutions. Informed consent was obtained from all patients prior to enrollment. For study entry, all patients were required to be 18 years of age or older. Patients were excluded if they had known infection with hepatitis B, hepatitis C or HIV. Patients were assessed for clinical disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Peripheral blood from a control group consisting of 10 healthy subjects (4 Caucasian, 4 Asian, 1 African-American and 1 Hispanic) was also analyzed. Peripheral blood from a control group consisting of 10 healthy subjects was also analyzed. Peripheral blood mononuclear cells (PBMCs) were prepared for flow cytometric analysis using Ficoll Paque (GE Healthcare, Piscataway, NJ) density gradient centrifugation and plasma of all individuals was stored at −20°C for assessment of anti-dsDNA and anti-DWEYS peptide antibody levels.

DWEYSVWLSN-streptavidin-allophycocyanin tetramers were generated incubating 25 μl biotinylated peptide (650 μM) (AnaSpec, San Jose, CA) with 75 μl allophycocyanin-labeled streptavidin (6.1 μM) (Molecular Probes, Eugene, OR) at 4°C overnight. Subsequently, peptide–APC complexes were separated from free peptide by gel filtration using a Bio-Gel P-30 spin column (Bio Rad, Hercules, CA).

Immunofluorescence labeling for multicolor flow cytometric analysis was performed by incubating PBMCs with anti-human monoclonal antibodies to: CD3/CD14/CD16 (Pacific Blue, UCHT-1/M5E2/3G8), CD19 (PerCP, SJ25C1), IgD (FITC, IA6-2) (BD PharMingen, San Diego, CA), CD27 (PE, CBL27/1), CD10 (FITC-labeled SJ5-1B4) (Invitrogen, Carlsbad, CA). In addition, the tetramer was used to label DWEYS-peptide-specific B lymphocytes. Labeling was performed in PBS/0.5%BSA/5 mM EDTA at 4°C for 30 minutes. DAPI (4′,6-diamidino-2-phenylindole dihydrochloride, Molecular Probes) was added before flow cytometric analysis (220 nM) to identify dead cells. Flow cytometric analysis was performed using the LSRII (Becton Dickinson, San Jose, CA) and FlowJo software (Treestar Inc, Ashland, OR). Doublets were excluded from analysis. Up to 2.5×106 events were acquired per analysis.


The ELISA assay for dsDNA-binding was performed as described [29]. Briefly calf thymus dsDNA, 25 μl per well at 100 μg/ml, was adsorbed to 96-well half area plates (Corning Life Science, Pittsburgh, PA), dried overnight at 37°C. DWEYS-peptide at 20 μg/ml in PBS was adsorbed to Immulon 2HB ELISA-plates (Thermo Electron Corporation, Waltham, MA) plates at 4°C overnight. The following day, plates were blocked with 2% BSA in PBS (dsDNA ELISA) or 3% FBS in PBS (peptide ELISA) for 1 h at 37°C. Plasma was diluted 1:300 (dsDNA ELISA) or 1:100 (peptide ELISA) in PBS before incubating plates for 1 h at 37°C. All ELISAs were developed with alkaline phosphatase conjugated goat anti-human IgG (Southern Biotechnology) and OD405 was measured using a Victor microplate reader (Perkin Elmer, Waltham, MA).

Statistical analysis

Frequencies of B cell subpopulations were calculated using FlowJo software (TreeStar). Differences in frequencies of tetramer-binding B cells between SLE patients and healthy controls and in different B cell subsets between patients grouped according to disease activity were determined using the unpaired, t tests. The Spearman's rank test was used to analyze if there was a correlation between the IgG anti-dsDNA-antibody and anti-DWEYS-antibody levels and the Mann Whitney U test to compare serological results of patients and normal individuals. The paired or unpaired t test as well as ANOVA were used to compare frequencies of tetramer-binding B cells within different B cell subsets. P values<0.05 were considered to be statistically significant. Data was analyzed using the GraphPad Prism4- (GraphPad, San Diego, CA).


Tetramer-binding B cells in peripheral blood of lupus patients

To determine the frequency of tetramer-binding B cells, peripheral blood cells of 22 patients with SLE (20 female, 2 male, 35.8±10.7 years old) and 10 healthy donors (8 female, 2 male, 32.2±7.9 years old) were analyzed by flow cytometry. The characteristics of the patient cohort are shown in Table 1. Both IgG anti-peptide antibody levels and IgG anti-dsDNA antibody levels determined by ELISA were significantly higher in SLE patients compared to healthy subjects (p<0.004, Figure 1A and p<0.0001, Figure 1B). Using routine clinical assays, 15 patients had elevated levels of anti-dsDNA antibodies (Table 1). Eleven patients had elevated anti-peptide antibody levels (at least 2SD above the mean of controls, Figure 1A). When all subjects were analyzed, a significant correlation between IgG anti-dsDNA and anti-peptide antibody levels was identified, (rs = 0.53, p = 0.002) although some patients exhibited a discordance between anti-DNA and anti-peptide reactivity.

Figure 1
Antibody titters.
Table 1
Patient characteristics

Flow cytometric analysis of peripheral blood cells performed concurrently using the gating strategy shown in Figure 2A demonstrated that all groups differed significantly (one way ANOVA p<0.002) a higher frequency of tetramer-binding B cells was present in SLE patients compared to healthy donors (0.085±0.065% vs. 0.038±0.010%, p<0.04, Figure 2B). Patients with moderately active disease (SLEDAI>4) had a significantly higher frequency of tetramer-binding B cells than patients with quiescent disease (SLEDAI≤4) (0.134±0.091% vs. 0.061±0.031%, p<0.02). However, even patients with inactive disease had a significantly elevated frequency of tetramer-binding B cells compared to healthy donors (p<0.04).

Figure 2
Tetramer-binding B cells.

Phenotype of tetramer-binding B cells in the peripheral blood of lupus patients

We are particularly interested in the regulation of B cells that have encountered antigen, as the checkpoints that are operative after antigen activation are less well studied. We, therefore, performed a detailed analysis of B cell subsets to determine the frequency of tetramer-binding B cells in antigen-inexperienced (CD27IgD+), or antigen-experienced subsets including IgD+CD27+ and Ig-class-switched (IgDCD27+) memory cell subsets and plasmablasts (CD27++CD19low) in individual patients with SLE. Since the CD27IgD cell subset, which appears to be enhanced in the peripheral blood of patients with SLE [36], [37] might include B cells which may have undergone class switching simply by exposure to TLR-ligands or cytokines such as IL-10 or IL-21 or BAFF [38], [39], [40], [41], this subset was considered to be heterogeneous. It probably includes both, antigen-naive and antigen-experienced B cells, and was therefore excluded from final analyses. This analysis was performed for SLE patients only as the frequencies were too low in control individuals to distinguish signal from background in most subpopulations. The gating strategy for these analyses is depicted in Figure 3.

Figure 3
Gating strategy used to characterize tetramer-binding B cells further.

The frequency of tetramer-binding cells was greater in both the antigen-naïve and the antigen-experienced subsets in patients with moderately active disease (n = 7) than in patients with quiescent disease (n = 15) (p<0.025 and p<0.005, respectively) (Figure 4 A and B). Interestingly, we observed a lower frequency of tetramer-binding B cells in the antigen-experienced population than in antigen-naïve population in both patients with quiescent disease and patients with moderately active disease (p<0.004 and p<0.013, respectively), demonstrating that there is a partial, although inadequate, maintenance of tolerance checkpoints after antigen activation even in active lupus patients (Figure 4 A and B). Indeed, every patient exhibited a decrease in frequency of tetramer-binding B cells in the antigen-experienced population compared to the antigen-naïve population.

Figure 4
Late checkpoints of B cell tolerance.

Interestingly, when we analyzed total number of tetramer-binding B cells with an antigen-experienced phenotype we found that patients with active disease had significantly higher numbers compared to patients with quiescent disease (p<0.025). In contrast, we observed no difference in the total number of tetramer-binding naïve B cells in the two patient groups (Figure 4C and D). This analysis may, however, be distorted by one patient with inactive disease and high numbers of naïve tetramer-binding B cells. If this one patient was excluded this difference became statistically significant as well (p<0.02).

We next asked whether the frequency of tetramer-binding cells was related to total B cell number. We reasoned that B cell lymphopenia might lead to increased BAFF levels and impaired negative selection. Contrary to our expectation, there was no relationship between total B cell number and frequency of tetramer-binding B cells (Figure 4E), although there was a relationship between total B cell number and the frequency of tetramer-binding B cells in antigen-experienced subsets (rS = 0.56, p<0.01,Figure 4F).

To analyze whether differences in ethnicity might associate with differences in B cell regulation Hispanic (n = 11) and African American (n = 11) patients were compared. No significant difference was observed between these ethnic groups with respect to frequency of tetramer-binding B cells within both the antigen-naive and the antigen-experienced subsets. With only 2 African-American patients with moderately active disease, it was not possible to ascertain the impact of ethnicity on the tolerance checkpoint at the antigen-to-antigen-naïve experienced junction.

We also studied the transitional to naïve B cell checkpoint in a subset of patients (n = 4 with quiescent disease and n = 3 with moderately active disease). In each patient, there was again a reduction in tetramer-binding B cells as the B cells matured from the transitional compartment to the naïve compartment (Figure 5). Although the number of individuals was limited, these differences almost reached statistical significance for patients with quiescent disease (p = 0.058) and for patients with moderately active disease (p = 0.05). Interestingly, while the frequency of tetramer-binding B cells was comparable in the transitional population for both patients with quiescent disease and patients with moderately active disease (0.36±0.13% vs. 0.42±0.24%, respectively), patients with moderately active disease exhibited a significantly higher frequency of tetramer-binding B cells in the naïve population (0.15±0.05% vs. 0.05±0.03%, p<0.02), suggesting a greater impairment at this checkpoint in patients with moderately active disease.

Figure 5
Early checkpoints of B cell tolerance.


The mechanisms underlying the failure of B cell tolerance as well as the contribution of different B cell subsets to the pathogenesis of SLE remain incompletely understood and the degree of heterogeneity in these parameters among lupus patients has not been extensively investigated. This study employed a tetrameric fluorochrome-labeled form of a dsDNA mimetope to characterize dsDNA-specific B cells obtained from the peripheral blood of patients with SLE. The tetramer was previously successfully used to track the peptide-specific B cell population in peptide-immunized BALB/c mice [33], [34]. Using the same tool, we were recently able to identify and enrich a rare peptide-specific B cell population in patients with SLE, and to demonstrate that the antibodies derived from these B cells bound peptide and were largely cross-reactive to dsDNA [35]. We now show that this cross-reactive tetrameric peptide can be used to investigate tolerance checkpoints in SLE patients. We noted that all lupus patients had a higher frequency of tetramer-binding B cells than did healthy controls.

A characterization of these tetramer-binding B cells confirmed the anticipated heterogeneity of patients with SLE. Most tetramer-binding B cells were antigen-naïve (70%), consistent with a previous study showing that lupus patients can have a high frequency of ANA-reactive B cells in the antigen-naïve B cell subsets even when in clinical remission or serologically inactive [25]. We identified a checkpoint for maintaining B cell tolerance that occurs during or after antigenic encounter. This checkpoint at the transition of autoreactive B cells from an antigen-naïve to an antigen-experienced compartment was present in lupus patients whether quiescent or moderately active. There was also a diminution of tetramer-binding B cells in lupus patients as B cells progressed from the transitional subset to the naïve subset although this was studied in a smaller number of patients. Interestingly, this checkpoint was more compromised in those patients with moderately active disease. It seems probable that multiple checkpoints are each partially compromised in lupus patients. Whether these checkpoints utilize similar or distinct mechanisms to tolerize autoreactive B cells, remains to be determined.

It has been reported that more active patients display high serum levels of BAFF [42]. We believe this may account for the greater impairment in the early transitional to naïve B cells checkpoint present in patients with moderately active disease. In mice, elevated BAFF levels permit the survival of autoreactive transitional B cells that would normally not mature to become naïve, immunocompetent B cells [43]. The increased BAFF levels in active patients may reflect increased BAFF production by dendritic cells exposed to nucleic acid-containing immune complexes, or could be related to disease-associated or therapy-associated B cell lymphopenia in both patients with active and patients with quiescent disease.

The decreased expression of FcγRIIb on memory B cells or immediate plasma cell precursors which occurs in approximately 50% of SLE patients may be one mechanism which contributes uniquely to the observed diminished tolerance in antigen-experienced B cells as FcγRIIb inhibits the B cell response in post-germinal center compartments and regulates plasma cell homeostasis [44], [45], [46], [47]. Classical mechanisms of B cell tolerance that have been demonstrated in the mouse such as follicular exclusion might also be impaired in patients with SLE due to lower FcγRIIb expression [48] or due to diminished competition from a non-autoreactive B cell population [49]. It is not clear if B cell lymphopenia, characterized by increased BAFF expression, affects late tolerance checkpoints as well.

It is necessary to note that patients in this study were on a variety of medications (Table 1). Whether these also contributed to aspects of the B cell repertoire cannot be assessed as the medication regimens in our patient cohort were too varied. Additional studies of patients selected for medication use will be needed to address this question.

Overall, lupus patients in this study displayed an increased frequency of autoreactive B cells in the early and late B cell repertoire independent of disease activity. Furthermore, an impairment of early selection checkpoints was associated with a greater disease activity and a significantly higher frequency of autoreactive B cells in the antigen-experienced B cell subsets. Given the phenotypic diversity of anti-DNA reactive B cells and the diverse tolerance mechanisms that are abrogated in murine models of SLE, the methodology we have used will be informative in longitudinal studies to track the changes in frequency and phenotype of autoreactive cells as individual patients progress from clinically quiescent disease to flare and back to quiescence. The methodology allows for an analysis of the representation of autoreactive B cells in different B cell subsets in a far larger number of patients than can be examining in methodologies that rely on cloning antibodies and expressing from individual B cells. Determining which mechanisms operate early in selection and which operate following antigen-activation, and which of these are impaired in SLE promises to be an important guide to identify immunologically distinct patient cohorts and to improve and customize therapeutic strategies.


We would like to thank Stella Stefanova assistance in flow cytometry and Sylvia Jones for assistance in preparation of the manuscript.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by the NIH and the Irvington Institute Fellowship Program of the Cancer Research Institute. This work was supported by the NIH and the Irvington Institute Fellowship Program of the Cancer Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Tan EM. Autoantibodies in pathology and cell biology. Cell. 1991;67:841–842. [PubMed]
2. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 1992;41:1690–1700. [PubMed]
3. Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol. 2007;19:11–23. [PMC free article] [PubMed]
4. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533. [PubMed]
5. Borrero M, Clarke SH. Low-affinity anti-Smith antigen B cells are regulated by anergy as opposed to developmental arrest or differentiation to B-1. J Immunol. 2002;168:13–21. [PubMed]
6. Culton DA, O'Conner BP, Conway KL, Diz R, Rutan J, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol. 2006;176:790–802. [PMC free article] [PubMed]
7. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177:999–1008. [PMC free article] [PubMed]
8. Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676–682. [PubMed]
9. Qian Y, Santiago C, Borrero M, Tedder TF, Clarke SH. Lupus-specific antiribonucleoprotein B cell tolerance in nonautoimmune mice is maintained by differentiation to B-1 and governed by B cell receptor signaling thresholds. J Immunol. 2001;166:2412–2419. [PubMed]
10. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109:1625–1633. [PMC free article] [PubMed]
11. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001;167:1886–1890. [PubMed]
12. Kuo P, Bynoe MS, Wang C, Diamond B. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol. 1999;29:3168–3178. [PubMed]
13. Santulli-Marotto S, Qian Y, Ferguson S, Clarke SH. Anti-Sm B cell differentiation in Ig transgenic MRL/Mp-lpr/lpr mice: altered differentiation and an accelerated response. J Immunol. 2001;166:5292–5299. [PubMed]
14. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–1377. [PubMed]
15. Nemazee D, Buerki K. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc Natl Acad Sci U S A. 1989;86:8039–8043. [PMC free article] [PubMed]
16. Nemazee D, Weigert M. Revising B cell receptors. J Exp Med. 2000;191:1813–1817. [PMC free article] [PubMed]
17. Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci U S A. 1980;77:1602–1606. [PMC free article] [PubMed]
18. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004;199:1577–1584. [PMC free article] [PubMed]
19. William J, Euler C, Leadbetter E, Marshak-Rothstein A, Shlomchik MJ. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J Immunol. 2005;174:6872–6878. [PubMed]
20. Peeva E, Michael D, Cleary J, Rice J, Chen X, et al. Prolactin modulates the naive B cell repertoire. J Clin Invest. 2003;111:275–283. [PMC free article] [PubMed]
21. Roark JH, Kuntz CL, Nguyen KA, Caton AJ, Erikson J. Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus. J Exp Med. 1995;181:1157–1167. [PMC free article] [PubMed]
22. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20:785–798. [PubMed]
23. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, et al. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med. 2006;203:393–400. [PMC free article] [PubMed]
24. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med. 2006;203:2255–2261. [PMC free article] [PubMed]
25. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201:703–711. [PMC free article] [PubMed]
26. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001;108:1061–1070. [PMC free article] [PubMed]
27. Gaynor B, Putterman C, Valadon P, Spatz L, Scharff MD, et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A. 1997;94:1955–1960. [PMC free article] [PubMed]
28. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103:19854–19859. [PMC free article] [PubMed]
29. Putterman C, Diamond B. Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J Exp Med. 1998;188:29–38. [PMC free article] [PubMed]
30. Sharma A, Isenberg D, Diamond B. Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens. Rheumatology (Oxford) 2003;42:453–463. [PubMed]
31. Yoshio T, Onda K, Nara H, Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:675–678. [PubMed]
32. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A. 2006;103:678–683. [PMC free article] [PubMed]
33. Newman J, Rice JS, Wang C, Harris SL, Diamond B. Identification of an antigen-specific B cell population. J Immunol Methods. 2003;272:177–187. [PubMed]
34. Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci U S A. 2005;102:1608–1613. [PMC free article] [PubMed]
35. Zhang J, Jacobi AM, Mackay M, Aranow C, Wang T, et al. Identification of DNA-reactive B cells in patients with systemic lupus erythematosus. J Immunol Methods. 2008;338:79–84. [PMC free article] [PubMed]
36. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol. 2007;178:6624–6633. [PubMed]
37. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 2008;58:1762–1773. [PubMed]
38. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007;19:268–274. [PubMed]
39. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol. 2004;172:5154–5157. [PubMed]
40. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3:822–829. [PubMed]
41. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med. 1994;179:757–762. [PMC free article] [PubMed]
42. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–2459. [PubMed]
43. Batten M, Groom J, Cachero TG, Qian F, Schneider P, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453–1466. [PMC free article] [PubMed]
44. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005;6:99–106. [PubMed]
45. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 2006;203:2157–2164. [PMC free article] [PubMed]
46. Rahman ZS, Alabyev B, Manser T. FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell, activity. J Immunol. 2007;178:897–907. [PubMed]
47. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007 [PubMed]
48. Paul E, Nelde A, Verschoor A, Carroll MC. Follicular exclusion of autoreactive B cells requires FcgammaRIIb. Int Immunol. 2007;19:365–373. [PubMed]
49. Schmidt KN, Hsu CW, Griffin CT, Goodnow CC, Cyster JG. Spontaneous follicular exclusion of SHP1-deficient B cells is conditional on the presence of competitor wild-type B cells. J Exp Med. 1998;187:929–937. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...